are an ‘‘emerging growth company’’ as defined under the U.S. federal securities laws and, as such, intend to comply with certain reduced public company reporting requirements for this and future filings.The underwriters have an option to purchase a maximum of 900,000 additional shares.Investing in our common stock involves risks.
commercialization to bring first-in-class and best-in-class monoclonal antibody therapeutics to patients who are underserved by current therapies.Key elements of our strategy include:•advance and commercialize ALD403 for the prevention of migraine;•seek a partner to advance and commercialize Clazakizumab as an option for first-line biologic therapy in autoimmune and inflammatory disease;-4-Table of Contents•advance ALD1613 for the treatment of Cushing’s Disease;•leverage our technology platform to discover future product candidates for areas of unmet need; and•build a leading biopharmaceutical company to transform current treatment paradigms.Risks Related to Our BusinessOur business is subject to numerous risks and uncertainties, including those highlighted in the section of this prospectus titled “Risk Factors” immediately following this prospectus summary.
30,2012201320132014(in thousands, except share and per share data)Consolidated Statements of Operations Data:Revenues:Collaboration and license agreements$20,067$18,796$13,972$48,269Operating expenses:Research and development30,66931,88325,54923,444General and administrative7,2177,6745,3219,054Total operating expenses37,88639,55730,87032,498Income (loss) from operations(17,819)(20,761)(16,898)15,771Other income (expense):Interest income101544730Other income—15815849Interest expense(88)———Other expense—(64)(45)—Total other income1314816079Net income (loss)$(17,806)$(20,613)$(16,738)$15,850Net income (loss) per share—basic$(19.54)$(21.14)$(17.21)$0.93Net income (loss) per share—diluted$(19.54)$(21.14)$(17.21)$0.56Weighted average number of common shares used in net loss per share—basic911,354975,158972,62417,006,362Weighted average number of common shares used in net loss per share—diluted911,354975,158972,62428,240,947-7-Table of ContentsAs of September 30, 2014ActualAs Adjusted(1)(2)(in thousands)Consolidated Balance Sheet Data:Cash, cash equivalents and investments$67,583$238,980Working capital63,052234,449Total assets75,824247,221Total liabilities10,91610,916Accumulated deficit(129,964)(129,964)Total stockholders’ equity64,908236,305(1)The as adjusted column reflects the sale of 6,000,000 shares of our common stock in this offering at an assumed public offering price of $30.48 per share, which is the
As a result, the trading price of our common stock could decline and you could lose part or all of your investment.Risks Related to Our Business and the Development and Commercialization of Our Product CandidatesWe have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.We are a clinical-stage biopharmaceutical company.
that our expenses will increase substantially as we:•continue the research and development of our product candidates, including clinical trials of ALD403;•seek regulatory approvals for our product candidates that successfully complete clinical trials;•establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize ALD403 or any of our future
product candidates if they receive regulatory approval; and•enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our
depends on our and any of our future collaborators’ success in:•completing clinical development and obtaining regulatory approval for ALD403;•entering into collaboration agreements with third parties with respect to our product candidates, including ALD403 and Clazakizumab, for their
development and commercialization in the United States or in international markets, and the continued financial and other support of these third parties under such collaboration agreements;•launching and commercializing ALD403, if approved, and successfully establishing sales, marketing and distribution infrastructure;•obtaining regulatory approvals for future product candidates that we discover and successfully develop;•establishing and maintaining supply and manufacturing relationships with third parties;•obtaining coverage and adequate reimbursement from third-party payors; and•maintaining, protecting, expanding and enforcing our intellectual property, including intellectual property we license from third parties.Because of the numerous risks and uncertainties associated with biologic product development, we are unable
available to us on acceptable terms, or at all, which would force us to delay, reduce or suspend our research and development programs and other operations or commercialization efforts.We are focused on the advancement of ALD403 through the clinical development process, as well as the evaluation of future product
including the following:•our ability to successfully complete this offering;•the rate of progress, recruitment and cost of our clinical trials and clinical success for ALD403 and any future product candidates;•the timing of, and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities;•the costs of commercialization activities if any of our product candidates, such as ALD403, receive regulatory approval, including sales, marketing and
Because successful-11-Table of Contentsdevelopment of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our product candidates.Furthermore, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe
The success of these product candidates will depend on several factors, including the following:•successful enrollment in, and completion of, clinical trials;•our ability to reach agreements with the FDA and other regulatory authorities on the appropriate regulatory path for approval for ALD 403;•receipt of approvals from the FDA and similar regulatory authorities outside the United States for these product candidates;•establishing commercial manufacturing arrangements with third parties;•successfully launching sales, marketing and distribution of any product candidate that may be approved, whether alone or in collaboration with others;•acceptance of any approved product by the medical community, third-party payors and patients and others involved in the reimbursement process, such as
the Centers for Medicare and Medicaid Services in the United States and the National Institute of Clinical Excellence in the United Kingdom;•effectively competing with other therapies;•achieving a continued acceptable safety profile of the product following approval, including intellectual property we license from third parties; and•obtaining, maintaining, enforcing and defending intellectual property rights and claims.If we do not achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to
We or any of our future collaborators may experience numerous unforeseen-12-Table of Contentsevents during, or as a result of, clinical trials that could delay or prevent our or any of our future collaborators’ ability to receive regulatory approval or commercialize our product
finding that our product candidates have unanticipated serious side-effects or other unexpected characteristics or that the patients are being exposed to unacceptable health risks;•regulators may not approve our or any of our future collaborators’ proposed clinical development plans;•regulators or institutional review boards may not authorize us, any of our future collaborators or our investigators to commence a clinical trial or
the data from our or BMS’s U.S. clinical trials, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt the development of a product candidate.The development and commercialization of biologic products is subject to extensive regulation, and we may not obtain regulatory
for many reasons, including because they:•may not deem the product candidate to be adequately safe or effective;•may not find the data from preclinical studies, clinical trials or CMC data to be sufficient to support a claim of safety and efficacy;•may not approve the manufacturing processes or facilities associated with the product candidate;-14-Table of Contents•may conclude that the long-term stability of the formulation of the drug product for which approval is being sought has been sufficiently demonstrated;•may change approval policies or adopt new regulations; or•may not accept a submission due to, among other reasons, the content or formatting of the submission.To market any biologics outside of the United States, we and any of our future collaborators must comply with the numerous and varying
if approved for commercial sale, will depend on a number of factors, including the following:•the efficacy and potential advantages compared to alternative treatments;•the prevalence and severity of any side-effects;•the price we or any of our future collaborators charge for our products;•the availability of third-party coverage and adequate reimbursement;•the convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these new therapies; and•the size and effectiveness of our sales, marketing and distribution support.If our product candidates are approved and do not achieve an adequate level of acceptance, we may not generate significant product
future collaborators’ inability to promptly obtain coverage and profitable payment rates from both government funded and private payors-19-Table of Contentsfor newly developed products could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.We may not be successful in our efforts to use and enhance our proprietary antibody platform to create a pipeline of
be suitable for clinical development, including as a result of their harmful side-effects, limited efficacy or other characteristics that make it unlikely such product candidates will receive regulatory approval or achieve commercial success.
Regardless of merit or eventual outcome, liability claims may result in:•decreased demand for any product candidates or products that we or any of our future collaborators may develop;•injury to our reputation and significant negative media attention;•withdrawal of patients from clinical trials or cancellation of trials;•significant costs to defend the related litigation;•substantial monetary awards;•loss of revenues; and•the inability to commercialize any products that we may develop.We currently have $20 million in product liability insurance coverage for our clinical trials, which may not be adequate to cover all
agreements with third parties with respect to our product candidates, including ALD403 and Clazakizumab, for their development and commercialization in the United States or in international markets.
candidates in international markets directly or with partners and will be subject to additional costs and additional risks related to international operations, including:•different regulatory requirements for drug approvals in foreign countries;•reduced protection for intellectual property rights;•unexpected changes in tariffs, trade barriers and regulatory requirements;•economic weakness, including inflation or political instability in particular foreign economies and markets;•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;•foreign taxes, including withholding of payroll taxes;-25-Table of Contents•foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing
process is expensive, time consuming and uncertain and may prevent us or our any of our future collaboration partners from obtaining approvals for the commercialization of some or all of our product candidates.Among other things, the research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug
In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including the following:•warning letters;•civil or criminal penalties and fines;•injunctions;•suspension or withdrawal of regulatory approval;•suspension of any ongoing clinical trials;•voluntary or mandatory product recalls and publicity requirements;•refusal to accept or approve applications for marketing approval of new drugs or biologics or supplements to approved applications filed by us;•restrictions on operations, including costly new manufacturing requirements; or•seizure or detention of our products or import bans.Prior to receiving approval to commercialize any of our product candidates in the United States or abroad, we and any of our future collaboration partners must demonstrate with substantial evidence from
facilities for our product candidates fail to comply with regulatory requirements of the FDA and/or other non-U.S. regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including the following:•warning letters;•civil or criminal penalties and fines;•injunctions;•suspension or withdrawal of regulatory approval;•suspension of any ongoing clinical trials;•voluntary or mandatory product recalls and publicity requirements;•refusal to approve pending applications for marketing approval of new drugs or supplements to approved applications filed by us;•restrictions on operations, including costly new manufacturing requirements; or•seizure or detention of our products or import bans.-31-Table of ContentsThe regulatory requirements and policies may change and additional government regulations
adversely affect:•our ability to set a price we believe is fair for our products;•our ability to generate revenues and achieve or maintain profitability; and•the availability of capital.Furthermore, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes.
introductions or announcements;•actions taken by regulatory agencies with respect to our product candidates, clinical trials, manufacturing process or sales and marketing terms;•variations in our financial results or those of companies that are perceived to be similar to us;•the success of our efforts to discover, acquire or in-license additional products or product candidates;•developments concerning our future collaborations, including but not limited to those with our sources of manufacturing supply and our future
companies or our industry generally;•trading volume of our common stock;•sales of our common stock by us or our stockholders;•changes in our board of directors or key personnel;•the expiration of contractual lock-up agreements;•changes in our capital structure, such as future issuances of debt or equity securities;•short sales, hedging and other derivative transactions involving our capital stock;•general economic, industry and market conditions in the United States and abroad;-35-Table of Contents•other events or factors, including those resulting from war, incidents of terrorism or responses to these events; and•the other risks described in this “Risk Factors” section.These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.
expenditures and other general corporate purposes, which may include the acquisition or licensing of other products, business or technologies.The failure by our management to apply these funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of
of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this prospectus, regarding, among other things:•our ability to obtain and maintain regulatory approval of our product candidates;•our ability to successfully commercialize any of our products that are approved;•the rate and degree of market acceptance of our products;•our estimates of our expenses, ongoing losses, future revenues, capital requirements and our needs for or ability to obtain additional financing;•our expected uses of the net proceeds to us from this offering;•our expectation that our existing capital resources and the net proceeds from this offering will be sufficient to enable us to complete our ongoing and
planned Phase 2b dose-ranging trials for ALD403;•our ability to obtain and maintain intellectual property protection for our products and product candidates;•the ability to scale up manufacturing of our product candidates to commercial scale;•our reliance on our future collaboration partners’ performance, over which we do not have control;•the actual receipt and timing of any milestone payments or royalties from our collaborators;•our ability to successfully establish and successfully maintain appropriate collaborations and derive significant revenues from those collaborations;•our reliance on third parties to conduct our clinical studies;•our reliance on third-party contract manufacturers to manufacture and supply our product candidates for us;•our ability to identify and develop new products and product candidates;•our ability to enroll patients in our clinical studies at the pace that we project;•our ability to retain and recruit key personnel;•our financial performance; and•developments and projections relating to our competitors or our industry.These risks are not exhaustive.
We currently estimate that we will use the net proceeds from this offering, together with our cash, cash equivalents and investments, as follows:•approximately $68 million for the development of ALD403, targeting CGRP for prevention of migraine, including our ongoing and planned Phase 2b
factors our board of directors may deem relevant.-44-Table of ContentsCAPITALIZATIONThe following table sets forth our cash, cash equivalents and investments and capitalization as of September 30, 2014:•on an actual basis; and•on an as adjusted basis to reflect the sale by us of 6,000,000 shares of common stock in this offering at an assumed public offering price of $30.48
per share, which is the last reported sale price of our common stock on the NASDAQ Global Market on January 7, 2015, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.You should read the information in this table together with the sections in this prospectus titled “Selected Consolidated
exercised, new options are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering.-46-Table of ContentsSELECTED CONSOLIDATED FINANCIAL DATAIn the following tables, we provide our selected consolidated financial data.
We expect our expenses will increase substantially in connection with our ongoing activities, as we:•conduct clinical trials for ALD403;•continue to evaluate our preclinical programs and advance at least one additional product candidate into the clinic;•enhance our proprietary antibody platform and conduct discovery and preclinical activities;•manufacture antibodies for our preclinical programs and clinical trials;•seek regulatory approval for our product candidates; and•operate as a public company.We will not generate revenues from product sales unless and until we or our future collaborators successfully complete development and obtain regulatory approval for one or more of our product candidates,
Our future funding requirements will depend on many factors, as we:•initiate or continue clinical trials of ALD403, our novel monoclonal antibody for prevention of migraine;•seek out a new partner to continue the development of Clazakizumab in autoimmune and inflammatory disease;•continue the research and development of our product candidates;•seek to discover additional product candidates;•seek regulatory approvals for our product candidates that successfully complete clinical trials;•establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize products which receive regulatory
These payments are not included in this table of contractual obligations.(4)Represents contractual obligations related to manufacturing our product candidates for use in our clinical trials, including long-term stability studies.Newly Adopted Accounting PronouncementsIn May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes
The compensation costs of these arrangements are subject to remeasurement over the vesting terms as earned.Prior to our IPO, the fair value of our common stock underlying stock options was historically determined by our board of directors, with assistance from management, based upon information available at